© 2000 American Heart Association, Inc.
Thrombosis |
Atherosclerosis Progression in LDL Receptor–Deficient and Apolipoprotein E–Deficient Mice Is Independent of Genetic Alterations in Plasminogen Activator Inhibitor-1
From the Divisions of Cardiology (H.S., D.T.E., E.G.N.) and Molecular Medicine and Genetics (D. Ginsburg), Department of Internal Medicine, and the Department of Human Genetics (D. Ginsburg) and Howard Hughes Medical Institute (R.W., D. Ginsburg), University of Michigan Medical Center, Ann Arbor, and Cardiovascular Therapeutics (D. Gordon), Parke-Davis Pharmaceutical Research, Ann Arbor, Mich.
Correspondence to David Ginsburg, MD, Department of Human Genetics, Howard Hughes Medical Institute, University of Michigan Medical Center, 4520 MSRB I, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail ginsburg{at}umich.edu
Abstract—Impaired fibrinolysis has been linked to atherosclerosis in a number of experimental and clinical studies. Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of plasminogen activation and has been proposed to promote atherosclerosis by facilitating fibrin deposition within developing lesions. We examined the contribution of PAI-1 to disease progression in 2 established mouse models of atherosclerosis. Mice lacking apolipoprotein E (apoE-/-) and mice lacking the low density lipoprotein receptor (LDLR-/-) were crossbred with transgenic mice overexpressing PAI-1 (resulting in PAI-1 Tg+/apoE-/- and PAI-1 Tg+/LDLR-/-, respectively) or were crossbred with mice completely deficient in PAI-1 gene expression (resulting in PAI-1-/-/apoE-/- and PAI-1-/-/LDLR-/-, respectively). All animals were placed on a western diet (21% fat and 0.15% cholesterol) at 4 weeks of age and analyzed for the extent of atherosclerosis after an additional 6, 15, or 30 weeks. Intimal and medial areas were determined by computer-assisted morphometric analysis of standardized microscopic sections from the base of the aorta. Atherosclerotic lesions were also characterized by histochemical analyses with the use of markers for smooth muscle cells, macrophages, and fibrin deposition. Typical atherosclerotic lesions were observed in all experimental animals, with greater severity at the later time points and generally more extensive lesions in apoE-/- than in comparable LDLR-/- mice. No significant differences in lesion size or histological appearance were observed among PAI-1-/-, PAI-1 Tg+, or PAI-1 wild-type mice at any of the time points on either the apoE-/- or LDLR-/- genetic background. We conclude that genetic modification of PAI-1 expression does not significantly alter the progression of atherosclerosis in either of these well-established mouse models. These results suggest that fibrinolytic balance (as well as the potential contribution of PAI-1 to the regulation of cell migration) plays only a limited role in the pathogenesis of the simple atherosclerotic lesions observed in the mouse.
Key Words: atherosclerosis • plasminogen activator inhibitor-1 • apolipoprotein E • low density lipoprotein receptors • transgenic mice
This article has been cited by other articles:
 |
|
 |
|
  M. Drinane, J. Mollmark, L. Zagorchev, K. Moodie, B. Sun, A. Hall, S. Shipman, P. Morganelli, M. Simons, and M. J. Mulligan-Kehoe The Antiangiogenic Activity of rPAI-123 Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque Circ. Res., February 13, 2009; 104(3): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. Fay, N. Garg, and M. Sunkar Vascular Functions of the Plasminogen Activation System Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1231 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Bodary, Y. Shen, M. Ohman, K. L. Bahrou, F. B. Vargas, S. S. Cudney, K. J. Wickenheiser, M. G. Myers Jr, and D. T. Eitzman Leptin Regulates Neointima Formation After Arterial Injury Through Mechanisms Independent of Blood Pressure and the Leptin Receptor/STAT3 Signaling Pathways Involved in Energy Balance Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Kairuz, M. N. Barber, C. R. Anderson, M. Kanagasundaram, G. R. Drummond, and R. L. Woods C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo Cardiovasc Res, June 1, 2005; 66(3): 574 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Eitzman, R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies, and D. Ginsburg Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice Circulation, April 12, 2005; 111(14): 1822 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider, M. Hayes, M. Wadsworth, H. Taatjes, M. Rincon, D. J. Taatjes, and B. E. Sobel Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1) J. Histochem. Cytochem., August 1, 2004; 52(8): 1091 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Cozen, H. Moriwaki, M. Kremen, M. B. DeYoung, H. L. Dichek, K. I. Slezicki, S. G. Young, M. Veniant, and D. A. Dichek Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death Circulation, May 4, 2004; 109(17): 2129 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel, D. J. Taatjes, and D. J. Schneider Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1979 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Grenache, T. Coleman, C. F. Semenkovich, S. A. Santoro, and M. M. Zutter {alpha}2{beta}1 Integrin and Development of Atherosclerosis in a Mouse Model: Assessment of Risk Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2104 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Schafer, K. Muller, A. Hecke, E. Mounier, J. Goebel, D. J. Loskutoff, and S. Konstantinides Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1 Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2097 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bot, J. H. von der Thusen, M. M.P.C. Donners, A. Lucas, M. L. Fekkes, S. C.A. de Jager, J. Kuiper, M. J.A.P. Daemen, T. J.C. van Berkel, S. Heeneman, et al. Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/- Mice Circ. Res., September 5, 2003; 93(5): 464 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsui, S. R. Rittling, H. Okamoto, M. Inobe, N. Jia, T. Shimizu, M. Akino, T. Sugawara, J. Morimoto, C. Kimura, et al. Osteopontin Deficiency Attenuates Atherosclerosis in Female Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1029 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dai, H. Guan, L. Liu, S. Little, G. McFadden, S. Vaziri, H. Cao, I. A. Ivanova, L. Bocksch, and A. Lucas Serp-1, a Viral Anti-inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury J. Biol. Chem., May 9, 2003; 278(20): 18563 - 18572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Deng, B. Martin-McNulty, D. A. Sukovich, A. Freay, M. Halks-Miller, T. Thinnes, D. J. Loskutoff, P. Carmeliet, W. P. Dole, and Y.-X. Wang Urokinase-Type Plasminogen Activator Plays a Critical Role in Angiotensin II-Induced Abdominal Aortic Aneurysm Circ. Res., March 21, 2003; 92(5): 510 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Askari, M.-L. Brennan, X. Zhou, J. Drinko, A. Morehead, J. D. Thomas, E. J. Topol, S. L. Hazen, and M. S. Penn Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction J. Exp. Med., March 3, 2003; 197(5): 615 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van Haperen, M. de Waard, E. van Deel, B. Mees, M. Kutryk, T. van Aken, J. Hamming, F. Grosveld, D. J. Duncker, and R. de Crom Reduction of Blood Pressure, Plasma Cholesterol, and Atherosclerosis by Elevated Endothelial Nitric Oxide J. Biol. Chem., December 6, 2002; 277(50): 48803 - 48807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. de Waard, E. K. Arkenbout, P. Carmeliet, V. Lindner, and H. Pannekoek Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1978 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Luttun, F. Lupu, E. Storkebaum, M. F. Hoylaerts, L. Moons, J. Crawley, F. Bono, A. R. Poole, P. Tipping, J.-M. Herbert, et al. Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 499 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Braun, B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice Circ. Res., February 22, 2002; 90(3): 270 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. DeYoung, C. Tom, and D. A. Dichek Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries Circulation, October 16, 2001; 104(16): 1972 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, P. M. Farrehi, and W. P. Fay Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice Circulation, June 26, 2001; 103(25): 3105 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Spooner, C. Albert, E. J. Benjamin, R. Boineau, R. C. Elston, A. L. George Jr, X. Jouven, L. H. Kuller, J. W. MacCluer, E. Marban, et al. Sudden Cardiac Death, Genes, and Arrhythmogenesis : Consideration of New Population and Mechanistic Approaches From a National Heart, Lung, and Blood Institute Workshop, Part II Circulation, May 22, 2001; 103(20): 2447 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Venugopal, R. Sharon, R. Abramovitz, A. Khasin, and R. Miskin Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction after injecting mice with kainate or adrenergic agents Cardiovasc Res, February 1, 2001; 49(2): 476 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Ploplis, I. Cornelissen, M. J. Sandoval-Cooper, L. Weeks, F. A. Noria, and F. J. Castellino Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attenuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1 Am. J. Pathol., January 1, 2001; 158(1): 107 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Eitzman, R. J. Westrick, Z. Xu, J. Tyson, and D. Ginsburg Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery Blood, December 15, 2000; 96(13): 4212 - 4215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Knowles and N. Maeda Genetic Modifiers of Atherosclerosis in Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2336 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C Felmeden and G. Y. Lip The renin-angiotensin-aldosterone system and fibrinolysis Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 240 - 244. [PDF]
|
|
|
|
|
|
A. Braun, B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice Circ. Res., February 22, 2002; 90(3): 270 - 276. [Abstract] [Full Text] [PDF]
|
|